B.Riley Financial Thinks Avinger’s Stock is Going to Recover

In a report released today, Marc Wiesenberger from B.Riley Financial maintained a Buy rating on Avinger (AVGRResearch Report), with a price target of $2.00. The company’s shares closed last Tuesday at $0.48, close to its 52-week low of $0.28.

According to TipRanks.com, Wiesenberger is ranked #388 out of 7766 analysts.

Currently, the analyst consensus on Avinger is a Moderate Buy with an average price target of $2.00.

See Insiders’ Hot Stocks on TipRanks >>

Avinger’s market cap is currently $45.91M and has a P/E ratio of -2.07.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avinger, Inc. manufactures catheter devices used to treat vascular diseases. It designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Ocelot MVRX, Ocelot PIXL, Pantheris, Wildcat, Juicebox and Kittycat 2. The company offers its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.

Read More on AVGR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed